| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
ASF-006 sodium (20 μM) exhibits strong inhibitory activity against VSV pseudotype infection with Omicron BA.2 or BA.4/5 subtypes on the surface, and has no significant cytotoxicity [1]. ASF-006 sodium has antiviral activity against different SARS-CoV-2 Omicron variants, but its activity against older strains (Wuhan-Hu-1) or distant coronaviruses (SARS-CoV) is limited [1]. ASF-006 sodium has strong antiviral activity against RSV-A, with IC50 values ranging from 0.05 to 0.2 μM when infecting A549, HEp-2, or Vero cells [1]. ASF-006 sodium has no antiviral activity against VSV (Rhabdoviridae), Nipah virus, or Sindbis virus [1]. ASF-006 sodium interacts with the S protein, interfering with its binding to the cell receptor ACE2 [1]. The binding affinity constants (Kd) of ASF-006 sodium to RBDBA.1 and SBA.1 proteins are approximately 60 μM and 5 μM, respectively [1].
|
|---|---|
| ln Vivo |
Sodium ASF-006 (100 mg/kg, intranasal, once daily for 3 days) reduced viral load in a mouse model of SARS-CoV-2 Omicron BA.1 infection [1].
|
| Animal Protocol |
Animal/Disease Models: K18-hACE2 (genetically modified to express human ACE2 under the control of the human cytokeratin 18 promoter; 6-week-old) were infected with SARS-CoV-2 Omicron BA.1[1]
Doses: 100 mg/kg (50 μL) Route of Administration: Intranasal; once daily; 3 days Experimental Results: A significant >3.5-fold reduction in viral load was observed in the lungs of treated mice compared to the vehicle group, as determined by quantitative RT-PCR. No signs of drug toxicity were observed. |
| References |
| Molecular Formula |
C125H80N8NA20O48
|
|---|---|
| Molecular Weight |
2921.79
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
O=C(C(CC1=C(C2=CC(C(O[Na])=O)=CC(C(O[Na])=O)=C2)NC3=C1C=CC=C3C4=CC(C(O[Na])=O)=CC(C(O[Na])=O)=C4)NC(CCOCC(COCCC(NC(C(O[Na])=O)CC(C5=C(N6)C(C7=CC(C(O[Na])=O)=CC(C(O[Na])=O)=C7)=CC=C5)=C6C8=CC(C(O[Na])=O)=CC(C(O[Na])=O)=C8)=O)(COCCC(NC(CC9=C(C%10=CC(C(O[Na])=O)=CC(C(O[Na])=O)=C%10)NC%11=C9C=CC=C%11C%12=CC(C(O[Na])=O)=CC(C(O[Na])=O)=C%12)C(O[Na])=O)=O)COCCC(NC(CC%13=C(C%14=CC(C(O[Na])=O)=CC(C(O[Na])=O)=C%14)NC%15=C%13C=CC=C%15C%16=CC(C(O[Na])=O)=CC(C(O[Na])=O)=C%16)C(O[Na])=O)=O)=O)O[Na]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3423 mL | 1.7113 mL | 3.4226 mL | |
| 5 mM | 0.0685 mL | 0.3423 mL | 0.6845 mL | |
| 10 mM | 0.0342 mL | 0.1711 mL | 0.3423 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
